ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma

Arrieta, V. A., Chen, A. X., Kane, J. R., Kang, S. J., Kassab, C., Dmello, C., Zhao, J., Burdett, K. B., Upadhyayula, P. S., Lee-Chang, C., Shilati, J., Jaishankar, D., Chen, L., Gould, A., Zhang, D., Yuan, J., Zhao, W., Ling, X., Burks, J. K., … Sonabend, A. M. (2021). ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. Nature Cancer, 2(12), 1372–1386. https://doi.org/10.1038/s43018-021-00260-2
Authors:
Víctor A Arrieta
Andrew X Chen
J Robert Kane
Seong Jae Kang
Cynthia Kassab
Crismita Dmello
Junfei Zhao
Kirsten B Burdett
Pavan S Upadhyayula
Catalina Lee-Chang
Joseph Shilati
Dinesh Jaishankar
Li Chen
Andrew Gould
Daniel Zhang
Jinzhou Yuan
Wenting Zhao
Xiaoyang Ling
Jared K Burks
Brice Laffleur
Christina Amidei
Jeffrey N Bruce
Rimas V Lukas
Jonathan T Yamaguchi
David Cieremans
Gerson Rothschild
Uttiya Basu
Matthew McCord
Daniel J Brat
Hui Zhang
Lee A D Cooper
Bin Zhang
Peter Sims
Tim F Cloughesy
Robert Prins
Peter Canoll
Roger Stupp
Amy B Heimberger
Craig Horbinski
Fabio M Iwamoto
Raul Rabadan
Adam M Sonabend
Affiliated Authors:
Andrew X Chen
Junfei Zhao
Pavan S Upadhyayula
Jinzhou Yuan
Wenting Zhao
Jeffrey N Bruce
David Cieremans
Gerson Rothschild
Uttiya Basu
Peter Sims
Peter Canoll
Fabio M Iwamoto
Raul Rabadan
Columbia Affiliation:
Subjects:
Glioblastoma (MeSH)
elink
Publication Type:
Article
Unique ID:
10.1038/s43018-021-00260-2
PMID:
35121903
DOI:
10.1038/s43018-021-00260-2
Journal:
Nature Cancer
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Scopus Record

Record Created: